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Glucose-6-phosphate dehydrogenase (G6PD) produces cellular NADPH, which is required for the biosyn-
thesis of fatty acids and cholesterol. Although G6PD is required for lipogenesis, it is poorly understood whether
G6PD in adipocytes is involved in energy homeostasis, such as lipid and glucose metabolism. We report here
that G6PD plays a role in adipogenesis and that its increase is tightly associated with the dysregulation of lipid
metabolism and insulin resistance in obesity. We observed that the enzymatic activity and expression levels of
G6PD were significantly elevated in white adipose tissues of obese models, including db/db, ob/ob, and diet-
induced obesity mice. In 3T3-L1 cells, G6PD overexpression stimulated the expression of most adipocyte
marker genes and elevated the levels of cellular free fatty acids, triglyceride, and FFA release. Consistently,
G6PD knockdown via small interfering RNA attenuated adipocyte differentiation with less lipid droplet
accumulation. Surprisingly, the expression of certain adipocytokines such as tumor necrosis factor alpha and
resistin was increased, whereas that of adiponectin was decreased in G6PD overexpressed adipocytes. In
accordance with these results, overexpression of G6PD impaired insulin signaling and suppressed insulin-
dependent glucose uptake in adipocytes. Taken together, these data strongly suggest that aberrant increase of
G6PD in obese and/or diabetic subjects would alter lipid metabolism and adipocytokine expression, thereby
resulting in failure of lipid homeostasis and insulin resistance in adipocytes.
Adipocytes are highly specialized cell type that maintains
whole-body energy homeostasis by regulating glucose and lipid
metabolism (60, 61). For a long time, adipocytes have been
considered as an energy depot that stores and mobilizes tri-
glyceride, a major energy fuel. Recently, adipocytes are also
being recognized as an endocrine tissue with the discoveries of
several adipocyte-secreted molecules, including lipid metabo-
lites and adipocytokines (55). Using these molecules, adipo-
cytes are able to communicate with other tissues and organs to
regulate lipid and glucose metabolism, energy balance, insulin
action, and reproduction.
To maintain lipid homeostasis, adipocytes carry out two re-
ciprocal biochemical processes: lipogenesis and lipolysis. These
two processes are tightly controlled by several hormones, lipid
metabolites, and nutritional conditions such as feeding and
fasting. With these signals, lipogenic transcription factors, in-
cluding ADD1/SREBP1c, LXRs, and PPAR actively partici-
pate in lipid metabolism in adipocytes. These transcription
factors are highly expressed in adipose tissue and play a key
role in adipocyte differentiation by coordinating lipogenic and
adipocyte-specific gene expression (50). Because lipogenesis is
tightly linked with adipogenesis, it is difficult to distinguish the
two processes—lipogenesis and adipogenesis—during adipo-
cyte differentiation.
Malonyl coenzyme A (malonyl-CoA) and NADPH are con-
sidered to be essential elements in lipogenesis (29, 54). Malo-
nyl-CoA, which is produced by acetyl coenzyme A (acetyl-
CoA) carboxylase (ACC), is a major substrate for long-chain
fatty acid synthesis. It also suppresses fatty acid oxidation by
inhibiting carnitine palmitoyltransferase (CPT-1) and acts as a
signal molecule in appetite regulation (24, 52, 53, 66). There-
fore, ACC2-null mice, with defects in malonyl-CoA synthesis,
show a higher fatty acid oxidation rate and a significant loss of
body fat mass (1, 2). NADPH also contributes to fatty acid
synthesis by supplying reducing power. NADPH is produced by
several enzymes, including malic enzyme (ME) and the first
two enzymes of the pentose phosphate pathway (PPP), glu-
cose-6-phosphate dehydrogenase (G6PD) and 6-phosphoglu-
conate dehydrogenase (6PGD) (54). Although isocitrate dehy-
drogenase (IDH) also generates NADPH, its major function is
irrelevant to lipogenesis (21, 54). Since NADPH is indispens-
able for the synthesis of fatty acids and cholesterol, it is plau-
sible to speculate that NADPH producing enzymes might be
associated with lipid metabolism disorders such as hyperlipid-
emia and lipid toxicity in metabolic diseases, including obesity
and diabetes.
Among the four NADPH-producing enzymes, G6PD is the
rate-limiting enzyme of PPP, and it is highly conserved in most
mammalian species (33). G6PD plays a key role in the main-
tenance of redox potential and cell survival via production of
NADPH and pentose phosphates (33). Previous researches on
G6PD have been mostly focused on erythrocytes since G6PD
deficiency in erythrocytes is a common human enzymopathy
which results from a mutation in the G6PD gene (8). Other
G6PD studies have been directed to cell growth, survival, and
redox regulation with nonerythrocyte cells, including fibro-
blasts, hepatocytes, and neuronal cells (9, 33, 38, 54). G6PD
also participates in reductive biosynthesis of fatty acids and
cholesterol. Regarding the lipogenic activity of G6PD, it has
been demonstrated that hepatic G6PD is regulated by nutri-
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tional signals, including high-carbohydrate diet, polyunsatu-
rated fatty acids, and hormonal signals such as insulin, gluca-
gon, thyroid, and glucocorticoids (33, 54). Furthermore, it has
been reported that G6PD-deficient patients show a decrease in
lipogenic rate and serum lipoprotein concentrations, implying
the importance of G6PD in fatty acid synthesis (15, 16). None-
theless, the functional roles of G6PD in adipocytes are poorly
understood.
In the present study, we demonstrated that both G6PD
mRNA and protein were highly expressed in adipocytes, and
their levels were significantly elevated in fat tissues of several
obese mouse models. In adipocytes, G6PD overexpression
stimulated the expression of adipocyte marker genes, as well as
the elevation of cellular free fatty acid (FFA), and triglyceride
(TG) and FFA release into the medium. In addition, expres-
sion levels of several adipocytokines, including tumor necrosis
factor alpha (TNF-), resistin, and adiponectin were sensi-
tively modulated by G6PD, which would then influence insulin
sensitivity in adipocytes. To determine more precisely the
physiological roles of G6PD, we suppressed G6PD expression
via small interfering RNA (siRNA). The resulting G6PD
knockdown impaired normal adipocyte differentiation by de-
creasing both intracellular lipid accumulation and adipocyte
marker gene expression. Therefore, these data suggest that
G6PD functions to enhance both lipogenesis and adipogenesis
and that high levels of G6PD in fat cells would lead to abnor-
mal lipid metabolism and insulin resistance, which are fre-
quently found in obese animals.
MATERIALS AND METHODS
Cell culture. 3T3-L1 cells were grown to confluence in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% bovine calf serum (BCS;
Gibco-BRL). Differentiation of 3T3-L1 cells was induced as described previously
(30). Briefly, after 2 days of postconfluence, 3T3-L1 cells were incubated with
DMEM containing 10% fetal bovine serum (FBS; Gibco-BRL), 3-isobutyl-1-
methylxanthine (500 M), dexamethasone (1 M), and insulin (5 g/ml) for
48 h. Culture medium was changed every other day with DMEM containing 10%
FBS and insulin (5 g/ml). 3T3-F442A cells were maintained in DMEM con-
taining 10% BCS and were differentiated into adipocytes by addition of the
medium with 10% FBS and insulin (5 g/ml) when the cells were confluent (30).
Northern blot analysis and real-time RT-PCR. Total RNA was isolated with
TRIzol reagent (Invitrogen/Life Technologies) according to the manufacturer’s
protocol. Each RNA was then denatured in formamide and formaldehyde, and
separated by electrophoresis on formaldehyde-containing agarose gels. After
electrophoresis, RNA was transferred to nylon membrane (Schleicher &
Schuell), which was cross-linked with UV and hybridized with DNA probes.
DNA probes were labeled by random priming method by using the Klenow
fragment of DNA polymerase I (Takara) and [-32P]dCTP (Amersham-Phar-
macia). cDNAs used as probes were those for G6PD, 6PGD, ME, IDH, ADD1/
SREBP1c, FAS, peroxisome proliferator-activated receptor  (PPAR),
C/EBP, aP2, HSL, and 36B4. To normalize RNA loading, blots were hybridized
with a cDNA probe for human acidic ribosomal protein, 36B4. For real-time
reverse transcription-PCR (RT-PCR) analysis, cDNAs were synthesized with
SuperScript First-Strand Synthesis System for RT-PCR kit (Invitrogen). It was
analyzed in a model iCycler Real-Time PCR Detection System (Bio-Rad) with
following primer sets: G6PD, sense (5-CGATGGCAGAGCAGGT-3) and an-
tisense (5-GATCTGGTCCTCACG-3); FAS, sense (5-TGCTCCCAGCTGC
AGGC-3) and antisense (5-GCCCGGTAGCTCTGGGTGTA-3); PPAR,
sense (5-TTGCTGAACGTGAAGCCCATCGAGG-3) and antisense (5-GTC
CTTGTAGATCTCCTGGAGCAG-3); aP2, sense (5-CAAAATGTGTGATG
CCTTTGTG-3) and antisense (5-CTCTTCCTTTGGCTCATGCC-3);
TNF-, sense (5-GCCACCACGCTCTTCTGCCT-3) and antisense (5-CTGA
TGGTGTGGGTGAGGAG-3); resistin, sense (5-CAGAAGGCACAGCAGT
CTTG-3) and antisense (5-GACCGGAGGACATCAGACAT-3); adiponec-
tin, sense (5-GGCAGGAAAGGAGAACCTGG-3) and antisense (5-GCCTT
GTCCTTCTTGAAGAG-3); GAPDH, sense (5-TGCACCACCAACTGCTT
AG-3) and antisense (5-GGATGCAGGGATGATGTTC-3); and cyclophilin,
sense (5-CAGACGCCACTGTCGCTTT-3) and antisense (5-TGTCTTTGG
AACTTTGTCTGCAA-3).
Western blot analysis. White adipose tissues and adipocytes were lysed with
TGN buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% Tween 20, 0.2% NP-40, 1
mM phenylmethylsulfonyl fluoride, 100 mM NaF, 1 mM Na3VO4, 10 g of
aprotinin/ml, 2 g of pepstatin A/ml, and 10 g of leupeptin/ml). Total cell
lysates were centrifuged at 12,000 rpm at 4°C for 15 min for the removal of fat
debris. The protein concentration was determined by BCA assay kit (Pierce).
Western blot analyses were conducted according to Amersham Life Science’s
protocol. The proteins were separated by electrophoresis on a sodium dodecyl
sulfate (SDS)-polyacrylamide gel and transferred to polyvinylidene difluoride
membranes (Millipore). After the transfer, the membranes were blocked with
nonfat milk containing PBST and were probed with primary antibodies against
G6PD, PPAR, glycogen synthase kinase 3 (GSK3), phospho-GSK3, Myc,
Flag, adiponectin, IR, IRS-1, Akt, phospho-Akt, and phosphotyrosine (4G10).
G6PD antibodies were purchased from Sigma Aldrich. PPAR, Myc, and Flag
antibodies were acquired from Santa Cruz Biotechnology. GSK3 and phospho-
GSK3 were purchased from Transduction Laboratory. IR, IRS-1, Akt, phos-
pho-Akt and 4G10 antibodies were purchased from Cell Signaling Technology.
Lastly, mouse adiponectin antibodies were provided by KOMED (Seoul, Korea).
The results were visualized with horseradish peroxidase-conjugated secondary
antibodies (Sigma Aldrich) and enhanced chemiluminescence.
G6PD enzyme assay. G6PD enzyme activities were determined by measuring
the rate NADPH production. Since 6PGD, the second enzyme of PPP, also
produces NADPH, both 6PGD and total dehydrogenase activity (G6PD plus
6PGD) were measured separately as previously described (64). G6PD activity
was calculated by subtracting the activity of 6PGD from the total enzyme activity.
Glucose-6-phosphate, 6-phosphogluconate, and NADP were obtained from
Sigma Aldrich. Protein levels were determined for each sample by using a BCA
assay kit (Pierce), and each enzyme activity was normalized by determining the
protein concentration.
Measurement of cellular lipid metabolites. Cell contents of triglycerides and
cholesterol in the 3T3-L1 cells were measured by using a TG and cholesterol
assay kit (Sigma Aldrich). The amount of free fatty acids was determined with a
NEFA assay kit (Roche). Each analysis was performed as recommended by the
manufacturer.
Retrovirus infection. Retroviruses were constructed in pBabe vectors by using
puromycin selectable markers. Viral constructs were transfected into BOSC cells
by using calcium-phosphate transfection method (48). Cells were incubated in
DMEM containing 10% FBS for 48 h. The cell culture medium was filtered
through a 0.45-m-pore-size filter, and the viral supernatant was used for infec-
tion of 3T3-L1 preadipocytes with Polybrene (4 g/ml). The cells were infected
for at least 12 h and allowed to recover for 24 h with fresh medium. The infected
cells were selected with puromycin (1 to 5 g/ml).
Adenovirus infection. G6PD adenovirus was produced by Neurogenex (Seoul,
Korea). G6PD cDNA was in frame fused with Flag epitope tag in its N terminus.
For adenovirus infection, 3T3-L1 adipocytes (at day 6 after differentiation) were
incubated with serum-free DMEM, and various titers of adenovirus for 16 h at
37°C. Then, the culture medium was replaced with fresh medium. Each experi-
ment was performed at 72 h after viral infection.
siRNA for G6PD. The sequences of the oligonucleotides used to create pSU-
PER-retro-siRNA-G6PD were designed from Oligoengine tools. Three sets of
mouse G6PD siRNA oligonucleotides are positioned at ca. 279 to 297, 546 to
564, and 1,149 to 1,167 nucleotides downstream from the transcription start site
of mouse G6PD cDNA. Three constructs were referred as pSUPER-retro-
siRNA-G6PD-2i (ca. 279 to 297 nucleotides), 5i (ca. 546 to 564 nucleotides),
and 11i (ca. 1,149 to 1,167 nucleotides), respectively. The siRNA sequences
were as follows: G6PD-2i-sense (5-GATCCCCGAAAGACCTAAGCTGGAG
GTTCAAGAGACCTCCAGCTTAGGTCTTTCTTTTTGGAAA-3), G6PD-2i-
antisense (5-AGCTTTTCCAAAAAGAAAGACCTAAGCTGGAGGTCTCT
TGAACCTCCAGCTTAGGTCTTTCGGG-3), G6PD-5i-sense (5-GATCCCC
CTGTCGAACCACATCTCCTTTCAAGAGAAGGAGATGTGGTTCGACA
GTTTTTGGAAA-3), G6PD-5i-antisense (5-AGCTTTTCCAAAAACTGTC
GAACCACATCTCCTTCTCTTGAAAGGAGATGTGGTTCGACAGGGG-
3), G6PD-11i-sense (5-GATCCCCCAGTGCAAGCGTAATGAGCTTCAAG
AGAGCTCATTACGCTTGCACTGTTTTTGGAAA-3), and G6PD-11i-anti-
sense (5-AGCTTTTCCAAAAACAGTGCAAGCGTAATGAGCTCTCTTGA
AGCTCATTACGCTTGCACTGGGG-3). These oligonucleotides were an-
nealed and then cloned into pSUPER-Retro vector (OligoEngine). The DNA
constructs were used to produce G6PD siRNA retrovirus. siRNA experiments
were performed as described by the manufacturer’s protocols (OligoEngine).
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Generation of G6PD enzyme dead mutants. Site-directed mutagenesis of
mouse G6PD cDNA was performed by using the QuikChange kit (Stratagene)
with the following mutagenic primers (mutated sites were underlined): G6PD-
S188F(m2) (5-CTGTCGAACCACATCTTCTCTCTTTTCCGTGACG-3) and
G6PD-K386E(m4) (5-CTTCCACCAACAGTGCGAGCGTAATGAGCTGGT
C-3).
Glucose uptake assay. Insulin stimulated glucose uptake in 3T3-L1 adipocytes
was determined by measuring [14C]2-deoxy-glucose uptake as previously de-
scribed (7). In short, adenovirus-infected 3T3-L1 adipocytes were incubated in
low-glucose DMEM containing 0.1% bovine serum albumin for 16 h at 37°C.
Cells were stimulated with or without 100 nM insulin for 1 h at 37°C. Glucose
uptake was initiated by the addition of [14C]2-deoxy-D-glucose at a final concen-
tration of 3 mol/liter for 10 min in HEPES buffer saline (140 mM NaCl, 5 mM
KCl, 2.5 mM MgCl2, 1 mM CaCl2, 20 mM HEPES [pH 7.4]). The reaction was
terminated by separating cells from HEPES buffer saline and [14C]2-deoxy-D-
glucose. After three washes in ice-cold PBS, the cells were extracted by 0.1%
SDS and subjected to scintillation counting for 14C radioactivity. The protein
concentration was determined with a BCA assay kit (Pierce), and the radioac-
tivities were normalized by determining each protein concentration.
RESULTS
Expression of G6PD mRNA in mouse tissues and adipocyte
cell lines. G6PD is known to be involved in lipogenesis by
producing NADPH. However, it has not been thoroughly in-
vestigated whether adipose tissues and fat cells express G6PD.
In order to examine the tissue distribution of G6PD mRNA,
we performed Northern blot analysis. As shown in Fig. 1A,
G6PD mRNA was highly expressed in adipose tissues. Also,
kidneys, lungs, and spleens expressed moderate levels of G6PD
mRNA (Fig. 1A). The mRNAs of 6PGD, ME, and IDH, other
NADPH-producing enzymes, were abundantly expressed in
adipose tissues, although their tissue distributions were not
the same. Compared to preadipocytes such as 3T3-F442A
and 3T3-L1, differentiated adipocytes prominently ex-
pressed G6PD mRNA, which was increased during adipogen-
esis (Fig. 1B). These observations implicate that G6PD might
play important roles in lipogenesis or adipogenesis in fat cells.
G6PD expression profiles in fat tissues of obese mice mod-
els. Obese animal models, including ob/ob, db/db, and diet-
induced obesity (DIO) mice, exhibit hyperlipidemia due to
abnormal increases of lipid metabolism and fat tissues. How-
ever, the enzymes that contribute to this increase in lipogenic
activity have not been clearly determined. Since G6PD is
highly expressed in adipocytes and plays a role in lipogenesis,
we decided to examine whether the level of G6PD expression
is changed in the fat tissues of obese animals. To answer this
question, we performed Northern blot analysis on subcutane-
ous and epididymal fat tissue of db/db mice. Surprisingly, the
mRNA expression levels of G6PD were remarkably increased
in both the subcutaneous (2.9-fold) and the epididymal (6.3-
fold) fat pads of db/db mice compared to those of db/ lean
littermates (Fig. 2A and B). In contrast, the mRNA levels of
other NADPH-producing enzymes, including IDH and ME,
were either slightly changed or even decreased in db/db mice.
Consistent with previous reports (43–45, 57–59), the mRNA
levels of FAS and ADD1/SREBP1c were reduced in the fat
tissues of db/db mice (Fig. 2A and B). We also investigated
G6PD mRNA levels in other obese mice models such as ob/ob
and DIO mice. Compared to lean mice, the mRNA levels of
G6PD were clearly increased in both obese models (Fig. 2C).
These results demonstrate that the level of G6PD mRNA is
explicitly elevated in fat tissues of various obese mice models,
implying that the stimulation of G6PD expression appears to
be associated with abnormal lipogenic activity in obese ani-
mals, leading to hyperlipidemia. Although more thorough in-
vestigations are required, we also observed that the expression
level of G6PD mRNA in human fat tissues shows a tendency to
increase with the degree of obesity (see Fig. S1 in the supple-
mental material).
To decide whether the protein levels and enzyme activity of
G6PD are also elevated in the fat tissues of obese mice, we
performed Western blot analysis and G6PD enzyme activity
assays. The protein levels of G6PD were also increased (3.3-
fold) compared to lean mice (Fig. 3A). As expected from the
mRNA and protein levels of G6PD, the enzymatic activity of
G6PD was enhanced in various fat depots of db/db mice (Fig.
3B). However, G6PD enzymatic activities of the liver and mus-
cle from db/db mice were insignificantly different from those of
lean mice (Fig. 3B). Furthermore, the enzymatic activities of
G6PD in fat tissues were at least 5- to 20-fold higher than that
of liver in both normal and obese mice. Taken together, these
FIG. 1. Expression of G6PD mRNA in mouse tissues and adipo-
cytes. (A) The indicated tissues were dissected from 10-week-old
C57BL/6J mice. Total RNA was isolated, and mRNA levels of indi-
cated genes were analyzed by Northern blot analyses. cDNA probes,
including G6PD, 6PGD, ME, IDH, ADD1, PPAR, and aP2, were
used. (B) Total RNAs were isolated from 3T3-F442A and 3T3-L1 cells
at the indicated time point after differentiation. Total RNA (20 g)
was analyzed for the expression of G6PD, PPAR, and aP2 by North-
ern blot analyses. Equal loading was confirmed by assaying for 36B4.
Pre, preadipocytes; Adi, adipocytes.
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observations suggest that both the expression level and the
enzymatic activity of G6PD are remarkably elevated in several
fat pads of obese animals, which may link to lipid dysregula-
tion.
Overexpression of G6PD stimulates adipogenesis and lipo-
genesis. Next, to examine functional roles of G6PD in adipo-
cytes, the effects of G6PD overexpression were investigated on
the lipogenic and/or adipogenic potential. Retrovirus overex-
pression of G6PD in 3T3-L1 cells enhanced 1.4-fold of its
enzyme activity in comparison to mock retrovirus-infected adi-
pocytes (Fig. 4A). On day 6 after the induction of adipocyte
differentiation, G6PD-overexpressed 3T3-L1 cells showed en-
hanced adipocyte morphology with larger and more lipid drop-
let accumulation (Fig. 4B). Northern blot analyses were per-
formed to investigate the change in lipogenic and adipogenic
gene expression profiles. As shown in Fig. 4C, G6PD overex-
pression markedly promoted the expression of most adipo-
cyte marker genes, including G6PD, FAS, ADD1/SREBP1c,
PPAR, and aP2. These observations suggest that G6PD over-
expression is able to stimulate adipogenesis with lipogenesis by
increasing both adipogenic and lipogenic gene expression.
Next, we determined the levels of lipid metabolites such as
TG, cholesterol, and FFAs in the absence or presence of
G6PD overexpression. In G6PD overexpressed adipocytes, cel-
lular FFAs and TG levels were elevated by 2- and 1.7-fold,
respectively (Fig. 4D and E). Interestingly, the level of FFAs
released into the cultured medium was also increased by 1.4-
fold (Fig. 4F). In contrast, cellular cholesterol levels were not
significantly changed (data not shown). These results indicate
that the level of G6PD expression is closely associated with the
levels of fatty acid metabolites, including TG and FFAs in
adipocytes. This implies that aberrant increase of G6PD in
obese subjects might promote circulating plasma FFA level,
FIG. 2. Expression of G6PD mRNA in fat tissues of obese mice
models, including db/db, ob/ob and diet-induced obesity (DIO). Sub-
cutaneous or epididymal fat pads were dissected from 16-week-old
db/, db/db, C57BL/6J, ob/ob, and DIO (C57BL/6J mice on a high-fat
diet for 9 weeks) mice. Total RNA was isolated, and the mRNA levels
of indicated genes were represented by Northern blots. (A) cDNA probes
including G6PD, ME, IDH, FAS, PPAR, and aP2 were used, and equal
loading was confirmed by assaying for 36B4. Subcutaneous fat, db/
(lanes 1 to 3) and db/db (lanes 4 to 7); epididymal fat, db/ (lanes 8 to 10)
and db/db (lanes 11 to 14). (B) Relative amounts of each mRNA were
quantified by measuring the ratio of each mRNA from db/db versus db/
mice after normalization with 36B4, respectively. The intensity of each
mRNA was determined by using a phosphorimager with Image-Master
software (Pharmacia Biomedical Systems). (C) Representative Northern
blots show the mRNA levels of G6PD and aP2. B6 stands for C57BL/6J.
Equal loading was confirmed by assaying for 36B4. FIG. 3. Protein levels and enzymatic activities of G6PD in obese
db/db mice tissues. (A) Total cell lysates were extracted from epidid-
ymal fat (white adipose tissues [WAT]) pads of db/ and db/db mice.
Immunoblotting was performed with G6PD, GSK3, and PPAR an-
tibodies. (B) Subcutaneous (Sub.), mesenteric (Mes.), and epididymal
(Epi.) fat pad, liver, and muscle tissues were dissected from db/ and
db/db mice. Tissue lysates were extracted and G6PD enzymatic activ-
ities were measured as described in Materials and Methods. The data
are presented as mean 	 the standard error (db/ 
 three, db/db 

four). The enzymatic activities were normalized by determining the
protein concentrations.
VOL. 25, 2005 FUNCTIONAL ROLES OF G6PD IN ADIPOCYTES 5149
 o
n
 O
ctober 12, 2014 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://m
cb.asm
.org/
D
ow
nloaded from
 
which is known to be a key cause of metabolic diseases, in-
cluding insulin resistance and hyperlipidemia and lipotoxicity
(3, 12, 13).
Knockdown of G6PD impairs adipogenesis. To verify
whether G6PD is associated with adipocyte differentiation, we
decided to knockdown G6PD by using siRNAs. We designed
three different G6PD siRNA constructs into pSUPER ret-
rovector (G6PD-2i, -5i, and -11i [see details in Materials and
Methods]). We infected 3T3-L1 cells with these siRNA retro-
viruses and examined their abilities to suppress G6PD protein
levels (Fig. 5A). Among these siRNAs, G6PD-11i most effec-
tively suppressed the expression of endogenous G6PD protein
(almost 90% reduction of G6PD protein), whereas G6PD-2i
and G6PD-5i partially decreased G6PD protein in 3T3-L1 cells
(Fig. 5A). Consistently, G6PD-11i effectively blunted G6PD
enzyme activity (data not shown).
Next, we investigated the effect of G6PD knockdown on
adipogenesis and lipogenesis. Consistent with our results that
G6PD is involved in adipogenesis and lipogenesis (Fig. 4),
3T3-L1 cells infected with G6PD-11i-siRNA retrovirus showed
attenuated adipocyte differentiation with a little lipid droplet
accumulation (Fig. 5B). Furthermore, the cellular levels of TG
and FFAs were significantly decreased in G6PD-11i-infected
3T3-L1 cells (Fig. 5C and D). Nonetheless, cellular cholesterol
levels showed no significant change (Fig. 5E), which is also
consistent with the results from G6PD-overexpressing cells.
To determine whether the reduction of G6PD expression
might affect adipogenic gene expression in 3T3-L1 cells, we
performed Northern blot analysis. As shown in Fig. 5F, the
mRNA expression levels of most lipogenic genes including
G6PD, 6PGD, ME, ADD1/SREBP1c, and FAS and those of
adipogenic genes including PPAR, C/EBP, and aP2 were
greatly decreased in G6PD-11i-infected 3T3-L1 cells, indicat-
ing that a certain amount of G6PD appears to be required for
the execution of both adipogenesis and lipogenesis in adipo-
cytes.
Catalytic activity of G6PD is required for adipogenesis. To
clarify whether the effect of G6PD on adipogenesis is associ-
ated with its catalytic activity or scaffolding activity, we exam-
ined the effects of G6PD enzyme activity-deficient mutants on
adipogenesis. On the basis of numerous studies from human
G6PD mutants (8, 46), we generated two mutants, G6PD-
S188F and G6PD-K386E (Fig. 6A). Mouse G6PD-S188F and
K386E mutants were named G6PD-m2 and G6PD-m4, respec-
tively. When G6PD-m2 or -m4 proteins were expressed to a
similar extent compared with the wild type, the enzyme activ-
ities of both G6PD mutants were almost abolished in COS7
cells (Fig. 6B and C). To further investigate whether the cat-
alytic activity of G6PD is required for adipogenesis, 3T3-L1
cells were infected with retroviruses containing G6PD-m2 or
-m4 and were induced to differentiate into adipocytes for 6
days. As shown in Fig. 6D, G6PD-WT-overexpressing 3T3-L1
FIG. 4. Overexpression of G6PD stimulates adipogenesis in 3T3-L1 cells. 3T3-L1 preadipocytes were infected with mock (pBabe) or G6PD
retrovirus (pBabe-G6PD), which were differentiated into mature adipocytes. (A) Proteins were extracted from pBabe or pBabe-G6PD-transduced
3T3-L1 adipocytes at 6 days after differentiation induction. G6PD and 6PGD enzymatic activities were measured as described in Materials and
Methods. The data are presented as means 	 standard errors (n 
 2); ❋ and ❋❋, P  0.1 and P  0.05, respectively (versus pBabe and
pBabe-G6PD). (B) Differentiated adipocytes were monitored by microscopic pictures with or without Oil Red O staining. (C) Northern blot
analyses were performed to evaluate mRNA levels of G6PD, FAS, ADD1/SREBP1c, PPAR, aP2, and HSL. Endo.G6PD stands for endogenous
G6PD mRNA. (D to F) Total cell lysates were collected from pBabe or pBabe-G6PD overexpressed 3T3-L1 adipocytes. Cellular FFAs (D), TGs
(E), and FFAs released into culture medium (F) were measured. The data were normalized by using protein concentrations. Each experiment was
repeated three times, and data are presented as means 	 standard errors (n 
 3).
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cells enhanced adipogenesis, whereas G6PD-m2- and -m4-
overexpressing cells were more or less differentiated into adi-
pocytes than mock-infected cells. In addition, we measured
G6PD enzymatic activity from wild-type and mutant G6PD-
overexpressing 3T3-L1 adipocytes. As expected, 3T3-L1 cells
overexpressing G6PD-m2 and -m4 exhibited lower G6PD ac-
tivity than wild-type G6PD-overexpressing adipocytes (Fig.
6E). Consistent with these observations, adipogenic and lipo-
genic gene expression was not enhanced by overexpression of
G6PD activity-deficient mutants (Fig. 6F). Therefore, it is
FIG. 5. Knockdown of G6PD suppresses lipogenic and adipogenic activities in 3T3-L1 adipocytes. Three synthetic siRNAs, which were
targeting different regions of G6PD mRNAs (see details in Materials and Methods), were constructed into pSUPER retrovector. Retroviral siRNA
constructs were used to infect 3T3-L1 cells, and the cells were differentiated into mature adipocytes. (A) Total cell lysates were collected from each
retroviral siRNA-infected 3T3-L1 adipocytes (mock, G6PD-2i, -5i, and -11i). Immunoblotting with G6PD antibody indicates the protein levels of
endogenous G6PD. (B) Mock or G6PD-11i siRNA-infected 3T3-L1 cells were induced into adipocytes, which were stained with Oil-Red O.
Macroscopic (top) and microscopic (bottom) views of Oil-Red O staining are shown. (C to E) Total cell lysates were extracted from mock or
G6PD-11i-infected 3T3-L1 adipocytes at 10 days after differentiation. Cellular TG levels (C), FFA levels (D), and cholesterol levels (E) were
measured. The data are presented as means 	 standard errors from three experiments. (F) Total RNAs were isolated from each retroviral siRNA
(mock, G6PD-2i, -5i, and -11i)-infected cells at 0, 6, and 10 days after differentiation. Northern blot analyses were performed to evaluate mRNA
levels of lipogenic (G6PD, 6PGD, ME, ADD1/SREBP1c, and FAS) and adipogenic (PPAR, C/EBP, and aP2) genes. Equal loading was
confirmed by assessing levels of 28S rRNA.
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likely that G6PD stimulates adipogenesis through its enzymatic
activity rather than by functioning as a scaffolding protein.
G6PD overexpression changes the expression of adipocyto-
kines. It has been demonstrated that abnormal increase of
cellular FFAs, TG, and FFA releases leads to the change of
adipocytokine production and insulin sensitivity in adipocytes
(3, 10, 13, 51). To examine the effect of G6PD overexpres-
sion on the expression or secretion of adipocytokines, we used
G6PD adenovirus (AdG6PD) to infect differentiated adipo-
cytes. Compared to mock adenovirus (AdMock)-infected adi-
pocytes, AdG6PD-infected adipocytes (50 PFU/cell infection)
expressed 1.5-fold more of G6PD protein (Fig. 7A). Accord-
ingly, the enzyme activity of G6PD was increased by adenoviral
G6PD expression (data not shown). Furthermore, adenoviral
G6PD expression in adipocytes increased the release of FFAs
into culture medium (Fig. 7B).
To determine the level of adipocytokine expression, we con-
ducted real-time RT-PCR and Western blot analyses in the
absence or presence of ectopic G6PD expression. Interestingly,
infection with AdG6PD dramatically suppressed the protein
FIG. 6. Catalytic activity of G6PD is required for adipogenesis. (A) Schematic representation of mouse G6PD mutants: G6PD-m2 (S188F) and
-m4 (K386E) were cloned into pCDNA 3.1()MycHis or pBabe vector. (B and C) After 2 days of transfection, the same amount of COS7 cells
were lysed for Western blot and enzyme activity assay. (B) Immunoblotting of G6PD expression in COS7 cells with either vector alone or
myc-tagged G6PD constructs (G6PD-WT, -m2, and -m4) with antibody to Myc epitope and G6PD. (C) G6PD enzymatic activities were measured
as described in Materials and Methods. The data are presented as means 	 standard errors (n 
 5). ❋, P  0.01 compared to mock-infected cells;
❋❋, P  0.05 compared to G6PD-WT-infected cells. (D to F) 3T3-L1 cells were infected with retroviruses containing mock-, G6PD-WT-, -m2-,
or -m4-infected cells and induced into adipocytes. (D) Differentiated adipocytes were monitored by analysis with or without Oil Red O staining.
(E) G6PD activity was measured from wild-type and G6PD mutant overexpressing 3T3-L1 adipocytes. The data are presented as means	 standard
errors (n 
 3). (F) Each mRNA expression level of G6PD, FAS, PPAR, and aP2 in mock-, G6PD-WT-, -m2-, or -m4-overexpressing 3T3-L1
adipocytes was measured by real-time RT-PCR. Values are normalized to the levels of GAPDH and cyclophilin and are represented as means 	
standard errors (n 
 3).
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and mRNA expression of adiponectin (Fig. 7A and C). Normal
expression of adiponectin is crucial to maintain insulin sensi-
tivity and to prevent atherosclerosis (5, 39, 47, 70). Also, re-
duction of adiponectin level is found in obese or diabetic
subjects (35, 41). Furthermore, real-time RT-PCR analyses
showed that mRNA levels of TNF- and resistin were greatly
elevated in G6PD-overexpressed adipocytes (Fig. 7C). Among
these adipocytokines, TNF- and resistin are well known to
induce insulin resistance in obese or diabetic animal models,
whereas adiponectin enhances insulin sensitivity (41, 42).
Therefore, these observations strongly suggest that increase of
G6PD levels in adipocytes would alter insulin sensitivity not
only by changing lipid metabolites but also by modulating
adipocytokine expression.
G6PD overexpression attenuates insulin signaling. Since
overexpression of G6PD in adipocytes increased the levels of
FFAs, TNF-, and resistin, which are key players in insulin
resistance (Fig. 7), we hypothesized that G6PD overexpression
would induce insulin resistance. To test this hypothesis, we ex-
amined the insulin signaling cascade with or without AdG6PD
infection. AdMock-infected adipocytes exhibited increased ty-
rosine phosphorylation of insulin receptor (IR) and IR sub-
strate 1 (IRS-1) and phosphorylation of Akt and GSK when
treated with insulin (Fig. 8A and B). In contrast, these phos-
phorylation events were significantly diminished in AdG6PD-
infected adipocytes (Fig. 8A and B).
It is well known that thiazolidinediones (TZDs), synthetic
ligands of PPAR, improve insulin sensitivity (20). Thus, we
decided to examine whether the strong insulin sensitizer, TZD,
is able to rescue insulin resistance in the presence of G6PD
overexpressed adipocytes. As shown in Fig. 8, rosiglitazone, a
member of TZD, clearly reversed the attenuated insulin sen-
sitivity by G6PD overexpression (Fig. 8A and B). These results
suggest that G6PD overexpression diminished insulin signal-
ing, which is probably associated with change of adipocytokine
expression, whereas TZD could reverse the insulin resistance
induced by G6PD overexpression (Fig. 8A and B).
To confirm these results, we conducted insulin stimulated
glucose uptake assay because it is a good measure of insulin
sensitivity in adipocytes. We determined the ability of
AdG6PD-infected 3T3-L1 adipocytes to uptake [14C]2-deoxy-
D-glucose in response to insulin. As shown in Fig. 8C, the fold
increases in insulin-stimulated glucose uptake were reduced in
G6PD-overexpressed adipocytes, and these responses were
rescued by rosiglitazone treatment. Together, these results im-
plicate that abnormal increase of G6PD expression in adipo-
cytes would interfere with insulin signaling and thereby induce
insulin resistance in obese subjects.
DISCUSSION
In the past several decades, obesity has become a common
health issue. Obesity is a major risk factor for metabolic dis-
eases, including hyperlipidemia, hypercholesterolemia, cardio-
vascular disease, and type II diabetes (28, 36, 72). In many
cases, metabolic diseases are closely associated with a failure of
lipid homeostasis. A balance between fat synthesis (lipogene-
sis) and fat breakdown (lipolysis/fatty acid oxidation) is critical
for the maintenance of lipid homeostasis that prevents lipo-
toxicity in the organs of overnourished individuals by confining
FIG. 7. Effects of G6PD overexpression on the expression of adipocytokines, including adiponectin, TNF-, resistin, and FFAs. 3T3-L1
adipocytes were infected with different titers of AdG6PD (0 to 50 PFU/cell) for 16 h. (A) Total cell lysates were isolated from AdG6PD-infected
3T3-L1 adipocytes at 72 h after infection. Protein samples were separated by SDS-polyacrylamide gel electrophoresis, and immunoblotting was
performed with antibodies to adiponectin, G6PD, and Flag, which detected only AdG6PD. (B) Released FFAs into culture medium were measured
with a NEFA assay kit (Roche). Obtained results were normalized by protein concentrations. The data are presented as means 	 standard errors
(n 
 3). (C) Total RNA was isolated from mock- or AdG6PD-infected adipocytes, and mRNA levels of indicated genes (G6PD, TNF-, resistin,
and adiponectin) were determined by real-time RT-PCR. Each mRNA amount was normalized with GAPDH and cyclophilin.
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excess lipid into adipocytes. Thus, defects in liporegulation
lead to hyperlipidemia or lipid toxicity found in obesity and
type II diabetes (28, 67). Consequently, tremendous research is
currently being devoted to the identification of molecular tar-
gets that behave as a “switch” that controls lipid metabolism
and to the development of drugs that specifically regulate lipid
metabolism. In spite of these efforts, molecular mechanisms
underlying lipid metabolism disorders in adipocytes have not
been clearly understood (14).
We suggest here that G6PD, one of the major NADPH-
producing enzymes, influences fat cell differentiation and lipo-
genesis, as well as insulin resistance, in obese subjects. Surpris-
ingly, G6PD was expressed most abundantly in fat tissues, and
its mRNA increased during adipocyte differentiation (Fig. 1).
Furthermore, the expression levels of G6PD mRNA and its
enzymatic activity were significantly elevated in the white fat
tissues of several obese animal models, including db/db, ob/ob,
and DIO mice (Fig. 2 and 3). These observations strongly sug-
gest that G6PD would play important roles in adipocytes, and
its abnormal expression would be linked to lipid metabolism
disorders frequently found in obese animals. We also demon-
strated that ectopic expression of G6PD stimulated both adi-
pogenesis and lipogenesis. Retrovirus overexpression of G6PD
in 3T3-L1 cells elevated lipid metabolites, including TG and
FFAs, and promoted mRNA expression of most adipocyte
marker genes, including FAS, ADD1/SREBP1c, aP2, and
PPAR (Fig. 4). Consistent with these results, G6PD knock-
down via siRNA system decreased cellular FFA and TG levels
and diminished adipogenic and lipogenic gene expression (Fig.
5), indicating that proper expression of G6PD is required for
adipogenesis as well as lipogenesis.
By producing NADPH, it appears that G6PD stimulates
lipogenic activity in adipocytes. However, the molecular mech-
anism by which G6PD overexpression increases cellular FFAs
and FFA release into medium is not understood. This might be
mediated by the hormone-sensitive lipase (HSL), since HSL is
responsible for hydrolysis of accumulated TGs into FFAs and
glycerol in adipocytes. In fact, we observed that G6PD-over-
expressed adipocytes significantly stimulated HSL expression
(Fig. 4C). Furthermore, the fact that FFA levels in adipocytes
were regulated by G6PD expression provides an important
clue to the link between the high level of G6PD in the fat
tissues of obese subjects and metabolic disorders. Many recent
studies have suggested that overproduced FFAs derived from
adipocytes cause insulin resistance and/or lipid toxicity, which
are linked with metabolic diseases such as type II diabetes,
cardiovascular disease, and dyslipidemia (3, 28, 60). More re-
cently, it has been shown that intracellular lipid accumulation
within skeletal muscle due to increase of circulating FFAs
correlates with insulin resistance independent of obesity (11).
Therefore, these results strongly suggest that an aberrant in-
crease of G6PD in adipocytes would elevate lipogenic activity,
thus overproducing FFAs and TGs, which might eventually
accelerate the onset of metabolic disorders.
In spite of these findings, it is difficult to distinguish adipo-
genesis and lipogenesis during fat cell development because
adipogenesis is tightly associated with lipogenesis in fat cells.
Although the molecular mechanisms of G6PD in adipogenesis
and lipogenesis are not well defined yet, there are several
possibilities for how G6PD overexpression is able to enhance
adipogenesis and lipogenesis. First, as a rate-limiting enzyme
of PPP, G6PD could affect cell growth and differentiation by
regulating the PPP process. Previously, it was reported that
dehydroepiandrosterone, an inhibitor of G6PD, interferes with
adipogenesis by reducing the NADPH/NADP ratio (18, 56).
Moreover, xylulose-5-phosphate, one of product of PPP, is well
known to be associated with regulation of lipogenesis (27, 65).
Thus, it is likely that overproduction of xylulose-5-phosphate
by G6PD enhanced lipogenesis. Second, it is also possible that
NADPH-dependent transcriptional regulators may stimulate
adipogenesis or lipogenesis. Recently, NADH-dependent acti-
FIG. 8. Effect of G6PD overexpression on insulin signaling (A and
B) and insulin-stimulated glucose uptake (C) in 3T3-L1 adipocytes.
3T3-L1 adipocytes were infected with mock or G6PD adenovirus. At 2
days after infection, cells were starved for 16 h with or without treat-
ment of rosiglitazone (10 M). (A) The cells were subsequently
treated with 100 nM insulin at 37°C for 10 min, and the cell lysates
were subjected to immunoblotting with anti-IR, anti-IRS1, antiphos-
photyrosine (4G10), anti-Akt, anti-pAkt, anti-GSK3, or anti-pGSK3
antibody. (B) Relative fold increases in insulin-stimulated phosphory-
lation of IR, IRS1, Akt, and GSK3. The levels of each phospho-
protein were normalized with those of total protein amounts.
(C) G6PD overexpression decreased insulin-stimulated [14C]2-deoxy-
glucose uptake. AdMock- or AdG6PD-infected 3T3-L1 adipocytes
were starved with serum-free DMEM for 12 h. Insulin-stimulated glucose
uptake assays were conducted as described in Materials and Methods.
The cpm results were normalized with protein concentrations. The fold
increases in insulin-stimulated glucose uptake were normalized by using
AdMock-infected adipocytes. The results are presented as a percentage of
the control (mean 	 standard error, n 
 2). Rosi, rosiglitazone.
5154 PARK ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 12, 2014 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://m
cb.asm
.org/
D
ow
nloaded from
 
vators or histone deacetylases have been identified, and several
target genes involved in the differentiation process are modu-
lated by these NADH-dependent coregulators (17, 25, 37, 71).
Lastly, it appears that G6PD could accelerate adipogenesis by
promoting free fatty acid metabolism, which might eventually
generate ligands of PPAR, a master transcription factor for
adipocyte differentiation. A similar idea has been demon-
strated that overexpression of the active form of ADD1/
SREBP1c, which coordinates most lipogenic genes, accelerates
adipogenesis in a nonadipogenic cell line by producing endog-
enous PPAR ligands (31).
As a major tissue for whole-body energy homeostasis, adi-
pose tissue integrates both central and peripheral metabolic
signals and orchestrates energy balance. Therefore, abnormal
increase or decrease of adipose tissue often causes systemic
disorders, also known as metabolic diseases. Adipose tissues
are also actively involved in many physiological and patholog-
ical processes by expressing various adipocytokines, including
leptin, TNF-, resistin, adiponectin, interleukin-6 (IL-6), and
FFAs (28, 40, 61). Therefore, adipose tissues locally influence
the equilibrium between lipogenesis and lipolysis and system-
atically contribute to whole-body energy homeostasis by an
endocrine mechanism. It is well known that certain adipocyto-
kines are important in provoking the insulin resistance found
in many obese and diabetic subjects. For example, the eleva-
tion in circulating inflammatory cytokines such as TNF- and
IL-6 mediates insulin resistance and is common in obesity (19,
22, 68). An increased level of TNF- in obese states leads to
insulin resistance via a number of mechanisms, including the
decrease of insulin signaling or GLUT4 expression (26, 62). In
addition, the newly identified resistin has been proposed to
link obesity and insulin resistance (32, 63). Resistin expression
is increased in obese animals and decreased by the antidiabe-
tes drug, rosiglitazone (63). Thus, it has been suggested that
TNF-, IL-6, and resistin participate in the regulation of glu-
cose metabolism and that high levels of their expression result
in insulin resistance and type II diabetes (4, 41, 49, 68). Unlike
these adipocytokines, adiponectin that regulates both glucose
and lipid metabolism increases insulin sensitivity (6, 40), and
its expression levels are inversely correlated with pathological
conditions such as obesity, diabetes, or atherosclerosis (23, 35).
In addition, many reports have shown that adiponectin treat-
ment improves insulin resistance, atherosclerosis and lipid me-
tabolism disorders in several animal models (5, 39, 47, 69, 70).
It is of interest to note that the levels of adipocytokines are
explicitly changed in G6PD-overexpressed adipocytes. As
shown in Fig. 7C, overexpression of G6PD in adipocytes ele-
vated the expression of TNF- and resistin mRNAs. In
contrast, both protein and mRNA levels of adiponectin were
decreased (Fig. 7A and C). The molecular mechanism(s)
underlying the G6PD-dependent changes in adipocytokine ex-
pression remains to be elucidated. Nonetheless, the idea that
anomalous increase of G6PD in adipocytes would induce in-
sulin resistance was confirmed by the observation that G6PD-
overexpressed adipocytes exhibited downregulated insulin sig-
naling and insulin-dependent glucose uptake (Fig. 8). Taken
together, these results strongly support the hypothesis that
aberrantly high expression of G6PD in fat tissues of obese
animals would result in metabolic disorders including hyper-
lipidemia and insulin resistance not only by increasing lipo-
genic activity but also by modulating adipocytokine expression.
Very recently, Koh et al. reported that IDPc is important for
modulating fat and cholesterol synthesis as well as adipogen-
esis by showing that overexpression of IDPc increases 3T3-L1
adipocyte differentiation, whereas reduced expression of IDPc
blocks adipogenesis (34). These results are somewhat similar
to our observations that overexpression of G6PD in adipocytes
promote lipogenesis and adipogenesis like IDPc overexpres-
sion, which could increase eventually cellular NADPH level.
However, several evidences suggest that IDPc would have dif-
ferent physiological roles from G6PD. First, compared to
G6PD, the mRNA level of IDPc is not significantly changed in
the fat tissue of obese mice models (Fig. 2). Second, the
mRNA level of G6PD was increased during adipocytes differ-
entiation (Fig. 1), whereas that of IDPc is not changed (34).
Furthermore, IDPc transgenic mice show lower fasting blood
glucose levels and improvement of glucose sensitivity com-
pared to wild-type mice, even though they exhibit obesity,
hyperlipidemia, and fatty liver. In contrast, G6PD overexpres-
sion caused insulin resistance in adipocytes (Fig. 8). In accor-
dance with this observation, G6PD overexpression increased
the expression of TNF- and resistin but decreased expression
of adiponectin, which is closely related to a decrease in insulin
sensitivity (Fig. 8). Thus, G6PD overexpression would lead to
abnormal lipid metabolism and insulin signaling, which are
different from IDPc overexpression.
In summary, we have established a novel link between G6PD
and lipid metabolism disorders in the adipocytes of obese an-
imals (Fig. 9). Our findings that G6PD expression is increased
in obese animals and that G6PD elevation in adipocytes
changes the levels of lipid metabolites provide strong evidence
that obesity induced lipid metabolism disorders and insulin
resistance is mediated, at least in part, by G6PD overexpres-
sion in fat tissues. Therefore, our observations that an abnor-
FIG. 9. Functional roles of G6PD in adipocytes and its impact on
obesity. Obese subjects stimulate G6PD expression in adipocytes and
enhance adiposity with elevation of TG and FFAs, which would affect
the expression of adipocytokines and metabolic syndromes, including
insulin resistance, hyperlipidemia, and lipotoxicity. See the text for
further explanation.
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mal increase of G6PD in adipocytes modulates lipid metabo-
lism and adipocytokine expression suggest a potential target in
the successful development of therapeutic treatment for obese
and diabetic patients.
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